Redeye comments on Initiator Pharma’s announcement that it will discontinue development of IP2018 and instead focus fully on its lead asset, pudafensine. We view the decision as a pragmatic prioritization that concentrates resources on the company’s most advanced and commercially relevant candidate. While the move simplifies the investment case and aligns with partner interest, it also reduces pipeline optionality, and we therefore remove the risk-adjusted contribution of IP2018 from our valuation model.
LÄS MER
